The Influence of Dopamine Beta-Hydroxylase Gene Polymorphism C.-979T>C (Rs1611115) on the Clinical Manifestations of Migraine

Abstract

Genetic factors definitely contribute to the aetiology and pathogenesis of migraine. A number of others studies have been conducted to better define genetic predisposition to dopamine metabolism disorders. The objective we had in this study was to evaluate the effect of the C and T alleles of DBH gene polymorphism rs1611115 (c.-979T>C) on the clinical characteristics of migraine. The retrospective study included 132 patients with migraine and control group included 348 unexamined subjects (population control), all living in Moscow and Moscow region. Genotypes were identified by PCR-RFLP method using Faul endonuclease. We demonstrated the role played by polymorphism at the promoter region of the DBH gene (rs1611115, allele T) in the development of the following clinical characteristics of migraine (p<0.05): allodynia, prodrome, postdrome, vomiting, aura, and the number of taken drugs. The data we obtained confirm the involvement of the dopaminergic system in the pathogenesis of migraine, particularly at the attack initiation stage.

Keywords: Migraine; Clinical characteristics; DBH gene; SNV; rs1611115

Introduction

Genetic factors definitely contribute to the aetiology and pathogenesis of migraine. In the last decade, great interest has been shown in genetic research in patients with migraine [1]. Significant success has been achieved, and genes responsible for the development of various forms of familial hemiplegic migraine have been identified [2]. A number of others studies have been conducted to better define genetic predisposition to dopamine metabolism disorders. The first study in this field was published in 1997, revealing the DRD2 (D2 dopamine receptor) gene polymorphism, which was found to be significantly more common in patients suffering from migraine with aura [3]. Subsequent studies broadened the scope of searching for potential research targets. All five receptor types were examined, and the next series of experiments failed to confirm changes in the D2DR gene; conflicting data were obtained on the D4 receptor. A study conducted by Todt in 2009 demonstrated that certain alleles of the gene encoding the dopamine transporter SLC6A3 were reliably associated with migraine with aura [4]. This transporter is responsible for reuptake of dopamine from the synaptic cleft, thus acting as a key regulator of dopaminergic activity. Most completed genetic studies have confirmed the role of polymorphism of the gene encoding the enzyme dopamine beta-hydroxylase (DBH), which stimulates the conversion of dopamine to norepinephrine [5-8].

Several SNPs found in the DBH gene were significantly more frequent in patients with migraine, and rs16111115 (often referred to as “-1021C/T” in literature sources), which is located in the promoter region, is the most interesting of them. The replacement of C with T changes the transcriptional activity of the gene and decreases plasma DBH levels. T allele homozygotes have the lowest plasma activity of DBH [9-13]. Some data were published recently demonstrating that patients with episodic or chronic migraine have increased plasma dopamine concentrations [14], which may be associated with lower activity of the DBH gene. The objective we had in this study was to evaluate the effect of the C and T alleles of DBH gene polymorphism rs1611115 (c.-979T>C) on the clinical characteristics of migraine.

Materials and Methods

Patients: The retrospective study included 132 patients with migraine living in Moscow and Moscow region, with a mean age of 41.6 ± 12.5 years. All those patients primarily visited the specialized University Headache Clinic (Moscow) for headache in the years 2012-2015.

The inclusion criteria were:

i. Migraine (chronic migraine according to the International Classification of Headaches III (ICHDI-II), 2013) [15];

ii. Age 18-69 years.

iii. The exclusion criteria were:
iv. Probable migraine, according to the ICHD-III;

v. Familial or sporadic hemiplegic migraine, according to the ICHD-III;

vi. Significant medical conditions other than migraine;

vii. Actual chronic migraine risk factor (current evidence of depression based on a Beck Depression Inventory (BDI) total score > 19, sleep disorders, stressful life events, caffeine overuse);

viii. Any prophylactic treatment for migraine for at least 3 months prior to the study.

Migraine was diagnosed by experienced neurologists based on the criteria of the ICHD-III. The patients were interviewed regarding the disease duration, the type of migraine, the frequency of migraine attacks (for the last 3 months), drugs used, underwent a clinical neurological examination and blood sampling for genotyping. The study was approved by the local ethics committee and all subjects gave informed consent to participate in the study. The control group included 348 unexamined subjects (population control), inclusion criteria: place of residence in Moscow or Moscow region. Patients and controls were age-matched. The study was conducted according to the Declaration of Helsinki Principles.

**Molecular genetic testing and data analysis**

The DNA extraction was performed according to the protocol for the DNA Magna™ DNA Prep 200 commercial kit (Isogene Laboratory LLC, Moscow, Russia). Genotypes were identified by PCR-RFLP method. The PCR was conducted according to the protocol for the HS Taq DNA polymerase mix (Evrogen Company, Moscow, Russia). Primers were synthesized by DNA Synthesis, LLC (Moscow, Russia): F: CTAGTCCAGCTGGAGAGATCT and R: TTGCGCATCATCCACCGTG. PCR conditions included initial denaturation (94 °C for 3 min), followed by 40 cycles consisting of denaturation (95°C for 20s), primer annealing (61°C for 10s), chain elongation (72°C for 15s), the reaction is completed with the final elongation (72°C for 5min). The restriction endonuclease Faul produced by SibEnzyme Ltd. (Novosibirsk, Russia) was used for digestion; the reaction was carried out under conditions recommended by the manufacturer. Restriction product size: CC=89+77, CT=166+89+77, TT=166. Products of restriction were separated in 2% agarose gel. Statistical analysis was performed using the Fisher test and Pearson's chi-squared test available in the WinPePi application package and using Student’s test, with the help of the MS Excel (2010) software package. Results were regarded as significant at p < 0.05.

**Results**

The following rates of alleles and genotypes were obtained in the study population (subjects / control): C - 0.715 / 0.745, T - 0.285 / 0.255; CC - 0.514 / 0.582; CT - 0.402 / 0.326; TT - 0.084 / 0.092. The distribution of genotype frequencies for rs1611115 in the study groups corresponded to Hardy–Weinberg equilibrium (patients: χ² = 0.0, p = 0.95; control: χ² = 3.49, p = 0.06). We did not find any significant difference in the frequencies of studied alleles (χ² = 0.969, p = 0.325) and genotypes (χ² = 1.710, p = 0.191) between patients and controls and therefore concluded that generally there is no association between the studied SNV and migraine. The genotype frequencies and the clinical characteristics of study subjects are presented in Table 1.

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Genotype</th>
<th>Fisher’s P (Two-Tailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CC</td>
<td>CT+TT</td>
</tr>
<tr>
<td>Controls (n=363)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females (n=120)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at onset</td>
<td>0.85</td>
<td>0.9</td>
</tr>
<tr>
<td>Aura (n=25)</td>
<td>0.14</td>
<td>0.24</td>
</tr>
<tr>
<td>Chronic (n=44)</td>
<td>0.31</td>
<td>0.37</td>
</tr>
<tr>
<td>Episodic (n=96)</td>
<td>0.69</td>
<td>0.63</td>
</tr>
<tr>
<td>Therapy-resistant (n=20)</td>
<td>0.13</td>
<td>0.17</td>
</tr>
<tr>
<td>Abuse (n=46)</td>
<td>0.32</td>
<td>0.35</td>
</tr>
<tr>
<td>Number of drugs (tablets)</td>
<td>24.27±9.30</td>
<td>42.66±18.34</td>
</tr>
<tr>
<td>Frequency of attacks</td>
<td>8.49±2.43</td>
<td>8.79±2.44</td>
</tr>
<tr>
<td>Attack duration, hours</td>
<td>33.16±6.43</td>
<td>37.19±6.70</td>
</tr>
<tr>
<td>Headache worsening time, minutes</td>
<td>101.28±22.84</td>
<td>94.79±22.33</td>
</tr>
</tbody>
</table>

Table 1: Representation of the clinical characteristics of migraine in the study sample and the rates of the rs1611115 replacement genotypes of the DBH gene. Statistically significant differences are shown in bold. Analysis of the association in the samples: control / group of patients having the symptom.
The Influence of Dopamine Beta-Hydroxylase Gene Polymorphism C.-979T>C (Rs1611115) on the Clinical Manifestations of Migraine

Discussion

The CT+TT genotypes were found to be associated with the following clinical characteristics of migraine (the T allele is inherited in a dominant fashion):

i. Number of taken drugs

ii. Aura (OR=2.43, CI95% [0.98-6.40]),

iii. Vomiting (OR=1.79, CI95% [0.99-3.24]),

iv. Alloodynia (OR=2.02, CI95% [1.10-3.74]),

v. Prodrome (OR=2.31, CI95% [1.15-4.74]),

vi. Postdrome (OR=2.21, CI95% [1.02-4.95]).

Conclusion

In conclusion, we demonstrated for the first time the role played by polymorphism at the promoter region of the DBH gene (rs1611115, allele T) in the development of the following clinical characteristics of migraine: allodynia, prodrome, postdrome, vomiting, aura, and the number of taken drugs. The data we obtained confirm the involvement of the dopaminergic system in the pathogenesis of migraine, particularly at the attack initiation stage.

Acknowledgement

The authors thank the subjects for their participation in this research study.

Conflict of Interest

No conflict of interest. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References


The Influence of Dopamine Beta-Hydroxylase Gene Polymorphism C.-979T>C (Rs1611115) on the Clinical Manifestations of Migraine


